A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516840-24-00

Acronym

D9441C00001

Enrollment

36

Registered

2025-02-13

Start date

2025-03-05

Completion date

2025-10-27

Last updated

2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Cardiovascular Disease, Chronic Kidney disease

Interventions

None listed

Sponsors

AstraZeneca AB

Lead SponsorINDUSTRY

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Bulgaria, Hungary, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026